Johnson & Johnson (JNJ) Announces Launch of the VIRTUGUIDE™ System

Johnson & Johnson (NYSE:JNJ) is one of the top cheap pharmaceutical stocks to buy now. On July 29, Johnson & Johnson (NYSE:JNJ) MedTech announced the launch of the VIRTUGUIDE™ System, an AI-powered, patient-matched solution that supports the Lapidus procedures.

Johnson & Johnson’s (JNJ) Long Dividend History Makes it a Strong Retirement Dividend Stock

A smiling baby with an array of baby care products in the foreground.

The Lapidus procedures are a kind of bunion surgery that joins two bones near the arch of the foot (the first metatarsal bone and the medial cuneiform) to realign them.

The system employs pre-operative planning software to “assess each patient’s bunion and make personalized recommendations for the intended correction”. The software was developed in collaboration with PeekMed.

Management stated that bunions affect nearly one-third of adults in the US, ranking it among the most common foot problems. However, the traditional Lapidus surgery for its treatment is often challenging.

The VIRTUGUIDE™ AI Lapidus System addresses these challenges by reducing surgical complexity and offering a streamlined approach.

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech.

The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.

While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.